Obesity
Why half of all workers may struggle to get weight-loss drug health insurance coverage
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Companies are increasing access to new blockbuster weight-loss drugs for employees, but size of employer may make a big difference in early access. Small businesses and their workers are often stuck […]
Read More
Promise of Eli Lilly’s weight-loss drug for sleep apnea adds another reason to own the stock
Eli Lilly ‘s weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world’s most valuable health-care company even after it’s been crushing the S & P 500’s performance over the past three years. The study results released by Eli Lilly on Wednesday highlight the […]
Read More
WeightWatchers CEO just sent an internal memo to employees as stock crashes, amid debt concerns, Oprah exit
Sima Sistani, CEO, WW International, August 16, 2023. Scott Mlyn | CNBC WeightWatchers CEO Sima Sistani has sent an internal memo to employees attempting to reassure them that the financial position of the company is solid and its new clinical business related to the threat of GLP-1 weight loss drugs is growing faster than expected. […]
Read More
Experts hesitate on weight loss ETFs amid the obesity drug boom
There may be a stronger case to invest in single stocks over exchange-traded funds in the weight loss space. Amplify ETFs and Roundhill Investments each filed a prospectus last week to launch funds focused on weight loss companies, a move that Strategas ETF and technical strategist Todd Sohn believes hinges on the performance of two […]
Read More
Thinking about taking new weight loss drugs? These are the big health risk decisions that will follow
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan Mcdermid | Reuters For all of the promise associated with new weight loss drugs such as Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound in treating obesity, there’s a very big risk printed right on […]
Read More
Most employer health plans don't cover new blockbuster weight loss drugs, but that's going to change
Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss. Despite the hefty price tag — typically between $1,000 to $1,500 a month — consumers are clamoring for drugs like Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound. This class of drugs, historically used to […]
Read More
Nvidia rally is fueling FOMO in the over-all marketplace, Evercore's Julian Emanuel warns
Evercore ISI’s Julian Emanuel thinks Nvidia’s monster rally is fueling a concern of lacking out in the marketplace. He finds consumers, including several who traded through the dot-com increase and subsequent collapse, are far more anxious about getting underinvested than overexposed appropriate now. “That is the first time that’s took place given that 2021 for […]
Read More
Eli Lilly's Zepbound is off to a strong start, but here's what needs to happen to push shares higher
Hopes are sky-high for Eli Lilly’s recently launched weight loss drug Zepbound. Investors will be tuning into the company’s fourth quarter earnings call on Feb. 6, eager to hear more about how that rollout is going. One key statistic will be the number of commercial health insurers providing coverage of the drug, which was approved […]
Read More
These stocks are trying to solve a major shortcoming of weight loss drugs: Shrinking muscle mass
One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat. What this means for patients over the long term isn’t fully known, but there are several pharmaceutical companies studying the side effect and hoping to develop therapies that might regulate the condition. In […]
Read More
‘Miracle drug’ euphoria: Specialists warn widespread use of fat decline medicine faces main hurdles
Two gurus see key difficulties facing the adoption of new being overweight medicine. Dr. Kavita Patel, a physician and NBC News health-related contributor, thinks new knowledge from Novo Nordisk on Ozempic’s means to hold off the development of long-term kidney disease is among the strongest supporting proof for secondary uses of the drug. On the […]
Read More